title: Resveratrol modulates autophagy and NF-κB activity in a murine model for treating non-alcoholic fatty liver disease.
abstract: In this study, we aimed to investigate the therapeutic effects and involved mechanisms of resveratrol on an established non-alcoholic fatty liver disease (NAFLD) murine model. Wild-type and autophagic mediator ULK1 heterozygous knockout mice were induced to have NAFLD by high-fat diet for 8weeks. After that, resveratrol treatment was applied with the high-fat diet feeding for another 4weeks. Typical features of NAFLD, including histological changes, fibrosis, insulin resistance, oxidative status, and inflammation were characterized. After-treatment with resveratrol showed ameliorative effects on all measured features of NAFLD, from histology, insulin resistance, glucose tolerance to oxidative stress and inflammation. resveratrol treatment also reduced the activity of nuclear factor-κB (NF-κB) through the restoration of its inhibitor IκBα. Partial inhibition of ULK1 expression impaired the ameliorative effects of resveratrol on hepatic histology, fibrosis, oxidative status, inflammation, and NF-κB activity. In conclusion, resveratrol improved NAFLD-caused hepatic injury partially through regulating autophagic and IκBα-NF-κB pathways.
authors: Department of Endocrinology, The First Affiliated Hospital of Xinxiang Medical University, Henan Province, China.
authors: Lake
authors: L
authors: Li
authors: Department of Endocrinology, The First Affiliated Hospital of Xinxiang Medical University, Henan Province, China.
authors: Jie
authors: J
authors: Hai
authors: Department of Endocrinology, The First Affiliated Hospital of Xinxiang Medical University, Henan Province, China.
authors: Zhiqiang
authors: Z
authors: Li
authors: Department of Endocrinology, The First Affiliated Hospital of Xinxiang Medical University, Henan Province, China.
authors: Yongli
authors: Y
authors: Zhang
authors: Department of Endocrinology, The First Affiliated Hospital of Xinxiang Medical University, Henan Province, China.
authors: Hua
authors: H
authors: Peng
authors: Department of Endocrinology, The First Affiliated Hospital of Xinxiang Medical University, Henan Province, China.
authors: Kun
authors: K
authors: Li
authors: Department of Endocrinology, The First Affiliated Hospital of Xinxiang Medical University, Henan Province, China. Electronic address: wengxiaogang@yahoo.com.cn.
authors: Xiaogang
authors: X
authors: Weng
mesh_terms: D000818:Animals; D001343:Autophagy / Q000187:drug effects*; D017931:DNA Primers; D059305:Diet, High-Fat; D004195:Disease Models, Animal; D005234:Fatty Liver / Q000188:drug therapy*; D007249:Inflammation / Q000503:physiopathology; D007333:Insulin Resistance; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D016328:NF-kappa B / Q000378:metabolism*; D018384:Oxidative Stress; D016133:Polymerase Chain Reaction; D000077185:Resveratrol; D013267:Stilbenes / Q000494:pharmacology* / Q000627:therapeutic use
chemical_list: D017931:DNA Primers; D016328:NF-kappa B; D013267:Stilbenes; D000077185:Resveratrol
keywords: ALT; AMP-activated protein kinase; AMPK; AST; Autophagy; GPx; GTT; HCC; IL; ITT; IκBα; MDA; NAFLD; NASH; NF-κB; PBS; Resveratrol; SREBP-1c; TNF; ULK1; UNC-51-like kinase 1; alanine aminotransferase; aspartate aminotransferase; glucose tolerance test; glutathione peroxidase; hepatocellular carcinoma; inhibitor of kappaB alpha; insulin tolerance test; interleukin; malondialdehyde; non-alcoholic fatty liver disease; non-alcoholic steatohepatitis; nuclear factor-kappaB; phosphate buffered solution; sterol regulatory element-binding protein-1c; tumor necrosis factor